Evidence map›Paper›PMID 42121903›Full record

ArticleCells2026

New Insights into the Development of Papillary Thyroid Cancer: The Roles of miR-1179 and ELF3.

Nicolas Henry, Nisrine Bahassou, Frédérick Libert, Geneviève Dom, Carine Maenhaut

Abstract read
In one paragraph

Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nicolas HenryIRIBHM J. E. Dumont, Université Libre de Bruxelles, 1070 Brussels, Belgium.ORCID 0009-0003-3423-5801
Nisrine BahassouIRIBHM J. E. Dumont, Université Libre de Bruxelles, 1070 Brussels, Belgium.
Frédérick LibertBRIGHTcore Facility, 1070 Brussels, Belgium.
Geneviève DomIRIBHM J. E. Dumont, Université Libre de Bruxelles, 1070 Brussels, Belgium.
Carine MaenhautIRIBHM J. E. Dumont, Université Libre de Bruxelles, 1070 Brussels, Belgium.

Funding

Fondation Jaumotte-Demoulin Université Libre de BruxellesFondation Rose et Jean Hoguet 2022-2024King Baudouin Foundation, Fund J.P. Naets 2021-J1813300-224095King Baudouin Foundation, Fund J.P. Naets 2023-J1813300-229649King Baudouin Foundation, Fund J.P. Naets 2025-J1813300-0026323Research credit CDR J.0150.25
6 · The paper itself

Abstract

Thyroid cancer is the most prevalent endocrine malignancy, and papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Although the prognosis is generally favorable, a better understanding of the molecular mechanisms involved in this pathology could lead to new treatment opportunities. Dysregulation of miRNA expression has been correlated with tumor development, and miR-1179 has been previously identified as one of the most downregulated miRNAs in PTC. This study aimed to explore the role of miR-1179 in thyroid tumorigenesis. miR-1179 was overexpressed in the TPC-1, B-CPAP, and HTori-3 thyroid cell lines to characterize its function and identify mRNA targets. The relevance of our data for human PTC was then addressed by analyzing TCGA and independent PTC. We showed that miR-1179 triggered apoptosis and inhibited cell migration. We identified ELF3 as a direct target of miR-1179 and other effectors, including NOTCH3 and CX3CL1. Finally, we revealed the existence of an inverse correlation between decreased expression of miR-1179 and increased expression of

Indexed as

DNA-Binding ProteinsMicroRNAsProto-Oncogene Proteins c-etsThyroid Cancer, PapillaryThyroid NeoplasmsTranscription FactorsApoptosisCarcinogenesisCell Line, TumorCell MovementGene Expression Regulation, NeoplasticHumansReceptor, Notch3DNA-Binding ProteinsELF3 protein, humanMicroRNAsProto-Oncogene Proteins c-etsReceptor, Notch3Transcription FactorsCX3CL1ELF3miR-1179miRNANOTCH3papillary thyroid carcinomathyroid

Identifiers

PMID42121903
PMCPMC13163138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.